Ventures

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

PCaVision, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. PCaVision eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, PCaVision addresses a significant global need for better prostate cancer diagnostics.

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

Garland Surgical addresses the challenge of hip replacement surgeries by offering an innovative solution that improves upon standard prostheses. Unlike traditional implants, the MaltaHip features four independent parts that provide enhanced mobility in three directions, reducing wear and minimizing the risk of dislocation. This implant offers a longer lifespan and greater functionality compared to standard prostheses. Importantly, it doesn't require a change to the normal surgical procedure, making it easier for surgeons to adopt.

OCCLUNOVA introduces a novel solution for chronic atrial fibrillation (AF), a condition affecting millions worldwide where the heart's upper chambers beat irregularly. Their implantable device aims to prevent strokes associated with AF by sealing off the left atrial appendage (LAA), where blood clots often form. Unlike traditional methods, which can cause complications due to their rigid frame, OccluNova's design uses a flexible balloon to fully seal the LAA. This innovative approach minimizes risks like pericardial effusions and incomplete closure, offering a safer option for AF patients.

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

AIDO enhances precision control during endoscopic procedures with its drive unit. Physicians can now maintain control of the endoscope shaft while operating tools, saving time and improving efficiency. This platform technology streamlines the control of instruments inserted through the endoscope's working channel, offering automatic insertion and precise control, ultimately improving patient safety and procedural outcomes.